Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
estimated completion

Description

Summary

The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of lesions located in the peripheral vasculature.

Official Title

Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature (ELEGANCE)

Details

A global prospective, non-randomized, open-label, multi-center Registry to collect Real-World Data, including health economic data, to support the use of commercially available drug-eluting BSC devices for the treatment of lesions located in the peripheral vasculature.

Keywords

Peripheral Vascular Diseases Vascular Diseases Peripheral Arterial Disease Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.

Eligibility

You can join if…

Open to people ages 18 years and up

  • Patients 18 years and older
  • Written informed consent (patient data release-form)
  • Use of any commercially available Boston Scientific drug-eluting device marketed for treatment of lesions in the peripheral vasculature and specified in the Registry Enrollment Guide

You CAN'T join if...

  • Life expectancy of <1 year

Locations

  • Ronald Reagan UCLA Medical Center not yet accepting patients
    Los Angeles California 90095 United States
  • Cedars Sinai not yet accepting patients
    Los Angeles California 90048 United States
  • PIH Health Good Samaritan Hospital accepting new patients
    Los Angeles California 90017 United States
  • Sutter Medical Center, Sacramento not yet accepting patients
    Sacramento California 95816 United States

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Boston Scientific Corporation
ID
NCT04674969
Study Type
Observational [Patient Registry]
Participants
Expecting 5000 study participants
Last Updated